Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesPhase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia
Cancer, 08/31/09
Thomas DA et al. – Vincristine sulfate liposome injection (VSLI) + dexamethasone is an effective salvage therapy option for relapsed/refractory
Methods- Phase 1 trial
- VSLI iv at 1.5, 1.825, 2.0, 2.25, or 2.4 mg/m2 iv in a 3 + 3 dose escalation design; dexamethasone (40 mg) was given on d 1-4 and 3 11-14 of each 4 w cycle
- 36 adults with relapsed/refractory ALL, all previously treated with conventional VCR, received at least 1 dose of VSLI
- The MTD of VSLE was 2.25 mg/m2
- 1 patient had grade 3 motor neuropathy, grade 4 seizure, and grade 4 hepatotoxicity at 2.4 mg/m2
- The most common toxicities attributed to VSLI included peripheral neuropathy (55%) and constipation (53%)
- A CR was achieved in 7 of 36 patients (19%)
- The CR rate was 29% for the 14 patients who underwent therapy as their first salvage attempt
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI)
Journal of Hematology & Oncology, 11/25/09
Association between defb1 gene haplotype and herpes viruses seroprevalence in children with acute lymphoblastic leukemia
Pediatric Hematology and Oncology, 11/25/09
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909
Journal of Clinical Oncology, 11/25/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor